Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). In Japan, the company Mochida started its commercialization for the treatment of depression started...
- Mechanism
- Curator reviewed · 2 references
Setiptiline is an antagonist at the α2 adrenergic receptor and at serotonin receptors. The antagonism of the α2 receptors likely relieves presynaptic inhibition of adrenergic neurotransmission, allowing for greater and longer sustained release of noradrenaline into the synapse. The antagonism of serotonin receptors may produce an upregulation of the receptors leading to an eventual increase in serotonergic signalling. The actual physiological mechanisms behind the antidepressant effect of setiptiline is unknown but the listed possibilities exist as likely explanations.
- Primary indication
- For the treatment of depression.Curator reviewed
- Formula / weight
- C19H19N · 261.368 g/mol (avg)
- Code names
- MO-8282 · Org 8282
Resolves to
GVPIXRLYKVFFMK-UHFFFAOYSA-NSMILESCN1CCC2=C(C1)C1=CC=CC=C1CC1=CC=CC=C21What you can answer from here — as of September 13, 2026
Which companies are running trials of Setiptiline, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account